These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

679 related items for PubMed ID: 8409438

  • 1. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P, Vourka-Karussis U, Weiss L, Slavin S.
    J Immunol; 1993 Nov 01; 151(9):4803-10. PubMed ID: 8409438
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L, Reich S, Slavin S.
    Cytokines Cell Mol Ther; 1999 Sep 01; 5(3):145-52. PubMed ID: 10641572
    [Abstract] [Full Text] [Related]

  • 3. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 4. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L, Reich S, Slavin S.
    Cytokines Cell Mol Ther; 1999 Sep 15; 5(3):153-8. PubMed ID: 10641573
    [Abstract] [Full Text] [Related]

  • 5. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ, Thompson JS, Jennings CD, Brown SA.
    Transplantation; 1995 Oct 27; 60(8):821-7. PubMed ID: 7482742
    [Abstract] [Full Text] [Related]

  • 6. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L, Glass B, Zeis M, Dreger P, Steinmann J, Löffler H, Schmitz N.
    Exp Hematol; 1998 Feb 27; 26(2):93-9. PubMed ID: 9472798
    [Abstract] [Full Text] [Related]

  • 7. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M, Uharek L, Glass B, Gaska T, Gassmann W, Mueller-Ruchholtz W.
    Bone Marrow Transplant; 1994 Nov 27; 14(5):711-5. PubMed ID: 7889004
    [Abstract] [Full Text] [Related]

  • 8. Effect of graft-versus-host disease on anti-tumor immunity.
    Schreiber KL, Forman J.
    J Immunol; 1990 Mar 01; 144(5):2018-26. PubMed ID: 1968493
    [Abstract] [Full Text] [Related]

  • 9. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y, Guo K, Chen Y, Song Z, Li J, Deng L.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug 01; 23(8):411-4. PubMed ID: 12411044
    [Abstract] [Full Text] [Related]

  • 10. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M, Uharek L, Glass B, Vosskötter W, Dreger P, Schmitz N, Steinmann J.
    Exp Hematol; 1998 Oct 01; 26(11):1068-73. PubMed ID: 9766447
    [Abstract] [Full Text] [Related]

  • 11. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.
    Morecki S, Yacovlev E, Gelfand Y, Vilensky A, Slavin S.
    Biol Blood Marrow Transplant; 2004 Jan 01; 10(1):40-8. PubMed ID: 14752778
    [Abstract] [Full Text] [Related]

  • 12. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L.
    Bone Marrow Transplant; 1990 Sep 01; 6(3):155-61. PubMed ID: 2252954
    [Abstract] [Full Text] [Related]

  • 13. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ.
    J Clin Invest; 1998 May 01; 101(9):1835-42. PubMed ID: 9576746
    [Abstract] [Full Text] [Related]

  • 14. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.
    Uharek L, Glass B, Gaska T, Zeiss M, Gassmann W, Löffler H, Müller-Ruchholtz W.
    Bone Marrow Transplant; 1993 May 01; 12 Suppl 3():S57-60. PubMed ID: 8124260
    [Abstract] [Full Text] [Related]

  • 15. Treatment of BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow and spleen cells.
    Palathumpat V, Holm B, Dejbakhsh-Jones S, Strober S.
    J Immunol; 1992 May 15; 148(10):3319-26. PubMed ID: 1578152
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
    Davenport C, George T, Devora GA, Morris MA, Gordon BE, Kumar V, Bennett M.
    Biol Blood Marrow Transplant; 1997 Dec 15; 3(6):294-303. PubMed ID: 9502296
    [Abstract] [Full Text] [Related]

  • 19. The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.
    Weiss L, Reich S, Slavin S.
    Bone Marrow Transplant; 1995 Sep 15; 16(3):457-61. PubMed ID: 8535320
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.